CompletedPhase 1NCT01782300

Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart

Studying Dengue fever

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Anna Durbin, MD, MD
Center for Immunization Research (CIR), Johns Hopkins School of Public Health
Intervention: TV003 Vaccine(biological)
Enrollment: 48 enrolled
Eligibility: 18-50 years · All sexes
Timeline: 2013 – 2016

Study locations (2)

Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
University of Vermont Vaccine Testing Center, Burlington, Vermont, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01782300 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials